FDA simplifies Covid

The Supreme Court Friday evening said that nationwide access to the abortion pill mifepristone should continue, rejecting a Texas district court’s call to remove the drug’s approval.

The stay will allow an appeals case and other legal challenges to play out without changing access to the drug, which can be used to induce an abortion in the early stages of pregnancy.

The court’s stay is a win for the FDA and the pharma industry, which had both warned that rescinding the approval of mifepristone or its generics could have ripple effects for other drugs. It’s also a victory for Danco Laboratories and GenBioPro, which make mifepristone, and had raised questions on how they would continue to market their products.

Unlock this story instantly and join 165,900+ biopharma pros reading Endpoints daily — and it's free.